<?xml version="1.0" encoding="UTF-8"?>
<ref id="B36-vaccines-07-00091">
 <label>36.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wang</surname>
    <given-names>B.Z.</given-names>
   </name>
   <name>
    <surname>Gill</surname>
    <given-names>H.S.</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Y.C.</given-names>
   </name>
   <name>
    <surname>Vassilieva</surname>
    <given-names>E.V.</given-names>
   </name>
   <name>
    <surname>Compans</surname>
    <given-names>R.W.</given-names>
   </name>
  </person-group>
  <article-title>Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand</article-title>
  <source>Clin. Vaccine Immunol. CVI</source>
  <year>2012</year>
  <volume>19</volume>
  <fpage>1119</fpage>
  <lpage>1125</lpage>
  <pub-id pub-id-type="doi">10.1128/CVI.00153-12</pub-id>
  <pub-id pub-id-type="pmid">22647270</pub-id>
 </element-citation>
</ref>
